Agenus to Participate at William Blair’s Biotech Focus Conference
Agenus (NASDAQ: AGEN) announces Dr. Steven O’Day's participation in a panel discussion on immuno-oncology at William Blair’s Biotech Focus Conference on July 12, 2022, at 4:10 PM EST. The conference will be held from July 12-13, 2022, at The St. Regis New York hotel, where Agenus will also conduct one-on-one investor meetings. Agenus focuses on developing therapies that harness the body's immune system to combat cancer and infections, aiming to expand patient access to cancer immunotherapy through innovative combinations and advanced manufacturing capabilities.
- None.
- None.
LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, will participate in a panel discussion on developing therapies for the next immuno-oncology targets at William Blair’s Biotech Focus Conference on Tuesday, July 12, 2022, at 4:10 PM EST.
The Conference will be held at The St. Regis New York hotel from July 12th – 13th, during which Agenus will also host one-on-one meetings with investors.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact
Ethan Lovell
Chief External Affairs & Communications Officer
339-927-1763
ethan.lovell@agenusbio.com
FAQ
What is Agenus participating in on July 12, 2022?
Who from Agenus is speaking at the conference?
Where is the William Blair Biotech Focus Conference being held?
What is the focus of Agenus' therapies?
When will the William Blair Biotech Focus Conference occur?
What investment opportunities will Agenus offer at the conference?
